Description
Aniracetam is a nootropic ampakine that exhibits anxiolytic and neuroprotective activities. Aniracetam acts as a positive allosteric modulator of AMPA receptors, slowing receptor deactivation; it also acts on D2 receptors, 5-HT2A receptors, and nicotinic acetylcholine receptors (nAChRs), likely displaying agonist activity. Aniracetam decreases anxiety in vivo in the condition fear stress test, elevated plus maze test, and in social interaction tests. Additionally, this compound inhibits H2O2-induced deficits in long-term potentiation and neuron viability. Aniracetam shows some clinical benefit in the enhancement of cognitive deficits associated with stroke and Alzheimer’s disease.
References
Wang YF, Li CC, Cai JX. Aniracetam attenuates H2O2-induced deficiency of neuron viability, mitochondria potential and hippocampal long-term potentiation of mice in vitro. Neurosci Bull. 2006 Sep;22(5):274-80. PMID: 17690727.
Jin R, Clark S, Weeks AM, et al. Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci. 2005 Sep 28;25(39):9027-36. PMID: 16192394.
Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8(1):70-89. PMID: 12070527.
Nakamura K, Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. PMID: 11412837.
Ito I, Tanabe S, Kohda A, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990 May;424:533-43. PMID: 1975272.
